Given the well-established role of the fibroblast growth factors (FGFs) and fibroblast growth factor receptors (FGFRs) signaling pathway in cancer progression, our findings show that FGF1 and FGFR2 were more significantly downregulated by antagonists compared with other ligands and receptors within the FGF/FGFR family (Fig. 4A). This evidence concerns the gene FGF1 and cancer.